Kobayashi Adam, Skowronska Marta, Litwin Tomasz, Czlonkowska Anna
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland.
Emerg Med J. 2007 Feb;24(2):96-9. doi: 10.1136/emj.2006.040204.
To determine the eligibility of patients with ischaemic stroke admitted to the 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland, for intravenous thrombolysis; to identify the major exclusions and assess whether organisational changes in the in-hospital stroke pathway and informative campaign in the local community and medical services can increase the number of patients treated; and to establish whether lack of previous experience with thrombolytic treatment or trials is predictive of the low proportion of patients treated.
A survey of the database of patients with stroke admitted during the first 30 months after the introduction of intravenous thrombolysis for acute ischaemic stroke was conducted to search for all eligible patients. This included patients admitted within 2 h of symptom onset (assuming a 1 h door-to-needle time), age <80 years, National Institute of Health Stroke Scale (NIHSS) Score of 5-22, seizures at onset, platelet count >100,000/ml, glycaemia 50-400 mg/dl and international normalised ratio (INR) <1.6. The number of eligible patients was compared with the number actually treated.
745 patients with acute ischaemic stroke were admitted during the study period. 18.4% were admitted within 2 h of symptom onset, 71% were aged <80 years, 55.4% had an NIHSS score between 5 and 22, 96.1% had INR <1.6, 98.9% had a platelet count >100,000/ml, 99.4% had blood glucose concentrations of 50-400 mg/dl and 97.4% had no seizures at onset. After adjusting for all inclusion criteria, 7.1% of the patients were found to be potentially eligible and 8.7% were actually treated (p = 0.25). Of the 65 treated patients, 63.1% were independent after 3 months, 16.9% died and none had a symptomatic intracranial haemorrhage.
The proportion of patients with ischaemic stroke treated with intravenous thrombolysis in a previously inexperienced centre was not lower than in other centres and in countries where this treatment has been provided for a longer period of time. The number of patients treated was higher than that estimated mainly owing to organisational changes introduced in our centre, allowing treatment of those admitted between 2 and 3 h after symptom onset.
确定波兰华沙精神病学与神经病学研究所第二神经科收治的缺血性中风患者是否适合静脉溶栓治疗;识别主要排除标准,并评估医院中风治疗流程的组织变革以及当地社区和医疗服务机构开展的宣传活动是否能增加接受治疗的患者数量;确定缺乏溶栓治疗经验或相关试验是否预示着接受治疗的患者比例较低。
对急性缺血性中风静脉溶栓治疗引入后的前30个月内收治的中风患者数据库进行调查,以寻找所有符合条件的患者。这包括症状发作后2小时内入院的患者(假设门到针时间为1小时)、年龄<80岁、美国国立卫生研究院卒中量表(NIHSS)评分为5 - 22分、发病时无癫痫发作、血小板计数>100,000/ml、血糖50 - 400mg/dl以及国际标准化比值(INR)<1.6的患者。将符合条件的患者数量与实际接受治疗的患者数量进行比较。
研究期间共收治745例急性缺血性中风患者。18.4%的患者在症状发作后2小时内入院,71%的患者年龄<80岁,55.4%的患者NIHSS评分在5至22分之间,96.1%的患者INR<1.6,98.9%的患者血小板计数>100,000/ml,99.4%的患者血糖浓度在50 - 400mg/dl之间,97.4%的患者发病时无癫痫发作。在调整所有纳入标准后,发现7.1%的患者可能符合条件,8.7%的患者实际接受了治疗(p = 0.25)。在65例接受治疗的患者中,63.1%在3个月后能够独立生活,16.9%死亡,且无一例发生有症状的颅内出血。
在一个此前缺乏经验的中心,接受静脉溶栓治疗的缺血性中风患者比例并不低于其他中心以及长期提供这种治疗的国家。接受治疗的患者数量高于预期,这主要归功于我们中心引入的组织变革,使得能够对症状发作后2至3小时内入院的患者进行治疗。